IMMX Immix Biopharma, Inc.
$8.05▼ -0.12%
Healthcare
Other
After hours
$8.06▲ +0.12%
Oct 27, 4:19 PM ET
Volume 1.15M
Avg Volume (10D) 1.29M
Key Metrics & Fundamentals
Market Cap
$667.37M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.85 - 15.10
% vs 50 MA
-28.82%
% vs 200 MA
-14.66%
RSI-14
32.7
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.59
Free Cash Flow
-$11.76M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$12.33M
COGS
–
Operating Exp
$12.46M
Operating Income
-$12.46M
EBIT
-$12.46M
Pretax Income
-$11.54M
Net Income
-$11.56M
EPS (Diluted)
-0.18
Price & Volume History
Loading chart…
Recent News
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Zacks · Oct 27, 2026 11:56 AM ET
Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst Revisions
Simply Wall St. · Oct 21, 2026 12:29 AM ET
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
GlobeNewswire · Oct 5, 2026 8:45 AM ET
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
MarketBeat · Oct 4, 2026 11:02 PM ET
Immix Biopharma Closes $125 Million Stock Offering
MT Newswires · Sep 30, 2026 5:36 PM ET
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
GlobeNewswire · Sep 30, 2026 5:15 PM ET
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
Stocktwits · Sep 29, 2026 1:48 PM ET
Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial
InvestorsHub · Sep 29, 2026 9:34 AM ET
Immix Biopharma Prices $125 Million Stock Offering
MT Newswires · Sep 29, 2026 8:30 AM ET
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
GlobeNewswire · Sep 29, 2026 7:05 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See IMMX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.